种族与肥厚型心肌病疾病表达及临床结局的关联
这项回顾性队列研究基于美国Sarcomeric Human Cardiomyopathy Registry 1989至2018年数据,纳入2467例黑人和白人肥厚型心肌病患者,比较种族与疾病表达、诊疗及结局的关联。发现黑人患者诊断更年轻、NYHA III/IV级心衰比例更高、遗传检测和室间隔减容术使用更少,且心衰发生风险更高,但卒中、室性心律失常、全因死亡或复合终点无差异。
要点
- 黑人肥厚型心肌病患者诊断年龄更轻,就诊时NYHA III/IV级心衰比例更高。
- 黑人患者遗传检测及室间隔减容术使用率更低,提示诊疗差异。
- 黑人种族与更高的NYHA III/IV级心衰发生风险独立相关。
核心结论
- 黑人肥厚型心肌病患者诊断更年轻、肌节突变携带率更低、功能性受限心衰负担更高,且侵入性室间隔减容术和遗传检测使用存在不公平。
- 黑人种族与更高的NYHA III/IV级心衰发生风险相关,但卒中、室性心律失常、全因死亡或整体复合终点无种族差异。
研究设计与样本
- 回顾性队列研究,纳入美国Sarcomeric Human Cardiomyopathy Registry 1989至2018年数据的黑人和白人肥厚型心肌病患者。
- 共分析2467例患者,其中黑人205例(8.3%),白人2262例(91.7%)。
主要发现
- 黑人患者诊断年龄平均36.5(18.2)岁,白人41.9(20.2)岁,P < .001。
- 黑人患者就诊时NYHA III/IV级心衰比例22.6%(36/205),白人15.8%(174/2262),P = .001。
- 黑人患者遗传检测率54.1%(111/205),白人62.1%(1404/2262),P = .03;肌节突变检出率26.1%(29/111) vs 40.5%(569/1404),P = .006。
- 黑人患者侵入性室间隔减容术比例14.6%(30/205),白人23.0%(521/2262),P = .007;ICD植入无种族差异。
- 黑人患者新发房颤比例17.1%(35/205),白人26.9%(608/2262),P < .001;NYHA III/IV级心衰风险HR 1.45(95%CI 1.08-1.94),多变量Cox回归HR 1.97(95%CI 1.34-2.88)。
临床怎么用
- 对黑人肥厚型心肌病患者应提高遗传检测和室间隔减容术的评估与可及性,关注心衰症状的早期识别与管理。
- 种族差异可能反映诊疗不公平或疾病通路差异,临床决策中需注意评估心衰负担并减少诊疗差异。
局限性
- 回顾性队列研究设计,可能存在残余混杂和信息偏倚。
- 仅纳入美国中心黑人和白人患者,结果外推需谨慎。
- 需进一步研究心衰风险差异是否与 ancestry-based 疾病通路、临床管理或结构性不公平相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Racial differences are recognized in multiple cardiovascular parameters, including left ventricular hypertrophy and heart failure, which are 2 major manifestations of hypertrophic cardiomyopathy. The association of race with disease expression and outcomes among patients with hypertrophic cardiomyopathy is not well characterized. OBJECTIVE: To assess the association between race, disease expression, care provision, and clinical outcomes among patients with hypertrophic cardiomyopathy. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study included data on black and white patients with hypertrophic cardiomyopathy from the US-based sites of the Sarcomeric Human Cardiomyopathy Registry from 1989 through 2018. EXPOSURES: Self-identified race. MAIN OUTCOMES AND MEASURES: Baseline characteristics; genetic architecture; adverse outcomes, including cardiac arrest, cardiac transplantation or left ventricular assist device implantation, implantable cardioverter-defibrillator therapy, all-cause mortality, atrial fibrillation, stroke, and New York Heart Association (NYHA) functional class III or IV heart failure; and septal reduction therapies. The overall composite outcome consists of the first occurrence of any component of the ventricular arrhythmic composite end point, cardiac transplantation, left ventricular assist device implantation, NYHA class III or IV heart failure, atrial fibrillation, stroke, or all-cause mortality. RESULTS: Of 2467 patients with hypertrophic cardiomyopathy at the time of analysis, 205 (8.3%) were black (130 male [63.4%]; mean [SD] age, 40.0 [18.6] years) and 2262 (91.7%) were white (1351 male [59.7%]; mean [SD] age, 45.5 [20.5] years). Compared with white patients, black patients were younger at the time of diagnosis (mean [SD], 36.5 [18.2] vs 41.9 [20.2] years; P < .001), had higher prevalence of NYHA class III or IV heart failure at presentation (36 of 205 [22.6%] vs 174 of 2262 [15.8%]; P = .001), had lower rates of genetic testing (111 [54.1%] vs 1404 [62.1%]; P = .03), and were less likely to have sarcomeric mutations identified by genetic testing (29 [26.1%] vs 569 [40.5%]; P = .006). Implantation of implantable cardioverter-defibrillators did not vary by race; however, invasive septal reduction was less common among black patients (30 [14.6%] vs 521 [23.0%]; P = .007). Black patients had less incident atrial fibrillation (35 [17.1%] vs 608 [26.9%]; P < .001). Black race was associated with increased development of NYHA class III or IV heart failure (hazard ratio, 1.45; 95% CI, 1.08-1.94) which persisted on multivariable Cox proportional hazards regression (hazard ratio, 1.97; 95% CI, 1.34-2.88). There were no differences in the associations of race with stroke, ventricular arrhythmias, all-cause mortality, or the overall composite outcome. CONCLUSIONS AND RELEVANCE: The findings suggest that black patients with hypertrophic cardiomyopathy are diagnosed at a younger age, are less likely to carry a sarcomere mutation, have a higher burden of functionally limited heart failure, and experience inequities in care with lower use of invasive septal reduction therapy and genetic testing compared with white patients. Further study is needed to assess whether higher rates of heart failure may be associated with underlying ancestry-based disease pathways, clinical management, or structural inequities.
引用
- Eberly LA, Day SM, Ashley EA, et al. Association of Race With Disease Expression and Clinical Outcomes Among Patients With Hypertrophic Cardiomyopathy. JAMA Cardiol. 2020. PMID: 31799990. doi:10.1001/jamacardio.2019.4638
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。